Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DAWN Day One Biopharmaceuticals	$6.32 -1.4%	$6.84	$6.08 ▼ $16.76	$649.73M	-1.3	1.13 million shs	1.50 million shs
IMVT Immunovant	$15.80 -0.4%	$15.07	$12.72 ▼ $34.47	$2.71B	0.61	1.22 million shs	1.91 million shs
MIRM Mirum Pharmaceuticals	$50.34 -0.9%	$44.31	$31.07 ▼ $54.23	$2.52B	0.95	491,937 shs	737,624 shs
OGN Organon & Co.	$9.77 -1.2%	$9.88	$8.01 ▼ $23.10	$2.57B	0.58	3.46 million shs	4.77 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DAWN Day One Biopharmaceuticals	-1.40%	-5.25%	+0.48%	-23.21%	-52.80%
IMVT Immunovant	-0.38%	+0.89%	+9.65%	-19.55%	-39.67%
MIRM Mirum Pharmaceuticals	-0.91%	+1.43%	+13.61%	+7.06%	+72.10%
OGN Organon & Co.	-1.22%	-2.59%	+15.59%	-36.30%	-52.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DAWN Day One Biopharmaceuticals	1.6823 of 5 stars	3.6	0.0	0.0	0.0	2.3	2.5	0.0
IMVT Immunovant	1.1996 of 5 stars	3.5	0.0	0.0	0.0	1.4	1.7	0.0
MIRM Mirum Pharmaceuticals	3.7426 of 5 stars	3.6	1.0	0.0	4.2	2.4	0.8	0.6
OGN Organon & Co.	4.6894 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	383.73% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	142.62% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	30.12% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	84.33% Upside

Current Analyst Ratings Breakdown

Latest DAWN, OGN, IMVT, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DAWN Day One Biopharmaceuticals	$131.16M	4.88	N/A	N/A	$4.99 per share	1.27
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
MIRM Mirum Pharmaceuticals	$336.89M	7.40	N/A	N/A	$4.70 per share	10.71
OGN Organon & Co.	$6.40B	0.40	$4.86 per share	2.01	$1.83 per share	5.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.71	N/A	N/A	N/A	-42.66%	-14.98%	-13.04%	7/8/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.39	2.61	1.03	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest DAWN, OGN, IMVT, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.82%	N/A	2.78%	N/A

Latest DAWN, OGN, IMVT, and MIRM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DAWN Day One Biopharmaceuticals	N/A	10.62	10.55
IMVT Immunovant	N/A	11.16	11.16
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DAWN Day One Biopharmaceuticals	87.95%
IMVT Immunovant	47.08%
MIRM Mirum Pharmaceuticals	N/A
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
DAWN Day One Biopharmaceuticals	6.20%
IMVT Immunovant	5.90%
MIRM Mirum Pharmaceuticals	14.36%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	95.08 million	Optionable
IMVT Immunovant	120	170.92 million	160.84 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	42.42 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable

DAWN, OGN, IMVT, and MIRM Headlines

Recent News About These Companies

ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 20 at 10:50 PM | prnewswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

June 20 at 5:18 PM | prnewswire.com

OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 20 at 4:00 PM | globenewswire.com

Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

June 20 at 12:35 PM | globenewswire.com

Faruqi & Faruqi Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGN

June 20 at 11:22 AM | prnewswire.com

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

June 20 at 9:06 AM | globenewswire.com

Levi & Korsinsky Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGN

June 20 at 9:00 AM | prnewswire.com

Cantor Fitzgerald Investment Advisors L.P. Decreases Position in Organon & Co. (NYSE:OGN)

June 20 at 7:19 AM | marketbeat.com

SG Americas Securities LLC Invests $829,000 in Organon & Co. (NYSE:OGN)

June 20 at 3:28 AM | marketbeat.com

Organon & Co. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights – OGN

June 19 at 4:00 PM | globenewswire.com

Investors who lost money on Organon & Co.(OGN) should contact The Gross Law Firm about pending Class Action - OGN

June 19 at 9:00 AM | prnewswire.com

ORGANON & CO. (NYSE: OGN) INVESTOR ALERT: Investors With Large Losses in Organon & Co. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

June 19 at 8:15 AM | globenewswire.com

Organon & Co. (NYSE:OGN) Given Average Rating of "Moderate Buy" by Brokerages

June 19 at 4:26 AM | marketbeat.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 18 at 11:40 PM | investing.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 18 at 10:48 PM | globenewswire.com

ROSEN, A RANKED AND LEADING FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

June 18 at 6:26 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN

June 18 at 11:14 AM | globenewswire.com

July 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against OGN

June 18 at 9:26 AM | globenewswire.com

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

June 18 at 8:38 AM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

June 18 at 7:28 AM | globenewswire.com

Exchange Traded Concepts LLC Raises Stock Holdings in Organon & Co. (NYSE:OGN)

June 18 at 3:58 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, OGN, IMVT, and MIRM Company Descriptions

Day One Biopharmaceuticals NASDAQ:DAWN

$6.32 -0.09 (-1.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.32 0.00 (0.00%)

As of 06/20/2025 04:20 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Immunovant NASDAQ:IMVT

$15.80 -0.06 (-0.38%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$15.80 0.00 (0.00%)

As of 06/20/2025 05:04 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Mirum Pharmaceuticals NASDAQ:MIRM

$50.34 -0.46 (-0.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$50.37 +0.03 (+0.06%)

As of 06/20/2025 04:52 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Organon & Co. NYSE:OGN

$9.76 -0.12 (-1.16%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$9.76 -0.01 (-0.10%)

As of 06/20/2025 04:15 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time